201604-0801CI 17. Isshiki T, Sakamoto S, Yamasaki A, et al. Incidence of acute exacerbation of idiopathic pulmonary fibrosis in patients receiving antifibrotic agents: real-world experience.
In a small Phase IIa trial, Insilico’s generative AI-designed idiopathic pulmonary fibrosis drug improved lung function and ...
Claims-based prevalence of disease progression among patients with fibrosing interstitial lung disease other than idiopathic pulmonary fibrosis in the United States. Ann Am Thorac Soc. 2022;19(7 ...
prevalence and outcomes between the sexes. According to a ... Researchers Identify Protein Connected to Aging and Idiopathic Pulmonary Fibrosis July 25, 2022 — Idiopathic pulmonary fibrosis (IPF ...
Medpage Today on MSN29d
CHEST Roundup: Diabetes in RA Patients Ups Risk of Interstitial Lung Disease"Due to the high prevalence of T2D in the RA population ... and cough intensity in idiopathic pulmonary fibrosis (IPF), ...
Therefore, this review presents the epidemiology of IPF ... denoting those miRNAs that are regulated by these mechanisms. Abbreviations: IPF, idiopathic pulmonary fibrosis; DNMT, DNA methyltransferase ...
Though oral pirfenidone reduces lung function decline and mortality from idiopathic pulmonary fibrosis (IPF), systemic exposure ... dizziness and dyspnoea, with higher incidence in the 100 mg two ...
(RTTNews) - Aileron Therapeutics, Inc. (ALRN), Wednesday announced positive topline data from the cohort 2 of Phase 1b study evaluating LTI-03 in patients with idiopathic pulmonary fibrosis (IPF).
Aileron Therapeutics' Phase 1b trial shows LTI-03 improved biomarkers and reduced SPD levels, indicating the potential to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback